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Abstract
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β
catalytic subunit. Recent studies showed that TGX-221 has anti-proliferative activity against
PTEN-deficient tumor cell lines including prostate cancers. The objective of this study was to
develop an encapsulation system for parenterally delivering TGX-221 to the target tissue through
a prostate-specific membrane aptamer (PSMAa10) with little or no side effects. In this study,
PEG-PCL micelles were formulated to encapsulate the drug, and a prodrug strategy was pursued
to improve the stability of the carrier system. Fluorescence imaging studies demonstrated that the
cellular uptake of both drug and nanoparticles were significantly improved by targeted micelles in
a PSMA positive cell line. The area under the plasma concentration time curve of the micelle
formulation in nude mice was 2.27-fold greater than the naked drug, and the drug clearance rate
was 17.5-fold slower. These findings suggest a novel formulation approach for improving site-
specific drug delivery of a molecular-targeted prostate cancer treatment.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)/ phosphatase and tensin homolog (PTEN)/Akt
pathway is highly involved in different types of cancer.1 PI3Ks are a family of enzymes that
phosphorylate PI(4,5)P2 (PIP2) to PI(3,4,5)P3 (PIP3). PIP3 is a lipid-signaling second
messenger that further activates of its downstream effectors, such as Akt, PDK1 and Rac1/
cdc42.2 The activation of Akt simulates cell growth, proliferation and survival.3 PTEN is a
phosphatase that dephosphorylates PIP3 back to PIP2.4 The missing function of PTEN
results in accumulation of PIP3 that mimics the activation of PI3K and triggers cell growth.
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PTEN deficiency is found in many types of cancers, such as prostate cancer (LNCaP), brain
cancer (U87MG) and breast cancer (BT549). 5-7
There are three classes of PI3K isoforms. The most commonly studied class I PI3Ks are
further divided into class IA and IB. Only class IA enzymes were clearly implicated in
human cancers. Class IA PI3K is consists of a p110 catalytic subunit and a regulatory
subunit. There are three highly homologous p110 catalytic isoforms: p110alpha, p110beta
and p110delta.8, 9 p110beta is a promising target in cancer therapy10, 11 and PTEN-deficient
tumor cells mainly depend on p110beta for signaling and growth, not p110alpha.9
The synthetic small molecule TGX-221 (Figure 1) is a potent, selective and cell membrane
permeable inhibitor of PI3K p110 beta catalytic subunit, which is critical for cell growth,
proliferation and tumorigenesis of PTEN-deficient tumor cells including prostate
cancers.12, 13 Therefore, PI3K p110 beta inhibitors have a great promise as novel
chemotherapeutic agents to treat PTEN deficient cancer cells.13 However, TGX-221 is
poorly soluble and requires organic solvents, such as DMSO or propylene glycol, for
intravenous injection, which may cause cardiac toxicity, unconsciousness, arrhythmia and
cardiac arrest.14
The therapeutic index of anticancer drugs is often very narrow, and the cytotoxic dose of the
drug in the desired tissues can be maintained over an extended period of time with minimal
side effects by targeted delivery and controlled drug release.15, 16 Both passive and ligand-
targeted nanoparticles have been developed for targeted delivery of cancer therapies.17, 18
Passively targeted nanoparticles can accumulate to a greater extent in tumors compared to
healthy tissues due to the enhanced permeability and retention (EPR) effect. The high
accumulation of nanoparticles in the tumor tissues is a consequence of the poorly aligned
endothelial cells allowing nanoparticles to escape from the blood circulatory system and to
pool in the tumor where there is a lack of effective lymphatic drainage.19, 20 Micelles are
attractive nanoparticles for the delivery of hydrophobic drugs, since they form
spontaneously in water after co-mixing the drug with an amphiphilic polymer. Both
polyethylene glycol (PEG) and polycaprolactone (PCL) are FDA approved biocompatible
and biodegradable materials. Micelles formed by PEG-PCL block copolymers have been
used as an effective drug delivery system for lipophilic molecules.21-23 Upon pooling in the
tumor, micelles will slowly release the drug and then dissolve into non-toxic degradation
products.24 Nanoparticles actively targeted via ligand binding can target cancer cells that
over express specific receptors or proteins.16 The ligands, monoclonal antibodies or
aptamers, can recognize and bind to complementary molecules expressed on the tumor cells.
We hypothesized that the delivery of a TGX-221 analogue to prostate cancer cells may be
improved if the drug is encapsulated in targeted-nanoparticles. The cancer-targeted
nanoparticles should be effective in suppressing tumor growth and metastasis with reduced
or lack of side effects associated with drug toxicities to normal tissues.
Aptamers are single- or double-stranded oligonucleotides that are modified to have high
binding affinity and specificity to the targets,25 and they have emerged as a novel class of
active targeting moieties for therapeutic and diagnostic applications in cancer treatment.
Prostate specific membrane antigen (PSMA) expression is confined primarily to prostate
tissues.26, 27 The expression of PSMA in other tissues, such as the brain and small intestines,
is approximately 1,000-fold less than that in the prostate.28 Prostate specific membrane
aptamer A10 (PSMAa10) has nM affinity to the membrane expressing PSMA, and it can be
used to achieve specific targeting of the nanoparticles to prostate cancer cells.29
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Due to the high biocompatibility of PEG-PCL block copolymers and the specific expression
of PSMA on prostate cancer cells, the combination of PEG-PCL and PSMAa10 in a
nanoparticle delivery system is promising for the targeted therapy of prostate cancer.
Materials and Methods
1. Materials
Azide poly(ethylene glycol) (MW: 5,800) was purchased from Polymer Source Inc.
(Quebec, Canada). Propargyl-dPEG®1-NHS ester was purchased from Quanta BioDesign
Ltd. (Powell, Ohio). PSMAa10 {5’-[NH2-(CH2)6-PEG18-GGG AGG ACG AUG GGG
AUC AGC CAU GUU UAC GUC ACU CCU UGU CAA UCC UCA UCG GC inverted
T]-3’, 2’F pyrimidines } was custom synthesized by Integrated DNA Technologies
(Coralville, IA). ε-caprolactone, IR-820, pyrene, 1-amino-3-butyne and 1-M HCl in diethyl-
ether were purchased from Sigma-Aldrich Co. (St. Louis, MO). Resazurin blue, silica gel
and the organic solvents were purchased from Fisher Scientific (Pittsburgh, PA).
2. TGX-221 and prodrug synthesis
All chemicals were used as received unless stated otherwise. NMR spectra were taken on a
400-MHz Bruker with the solvent peak as an internal reference. Mass spectra were run in
the Electrospray Ionization Mass Spectrometry (ESI-MS) mode or Atmospheric Pressure
Chemical Ionization Mass Spectrometry (APCI-MS) mode. Reactions that required an inert
atmosphere were carried out under dry argon with flame-dried glassware. Tetrahydrofuran
(THF) was freshly distilled over sodium-benzophenone. Dichloromethane (DCM), N, N-
dimethylformaldehyde (DMF) and triethylamine (TEA) were freshly distilled over CaH2.
The synthetic scheme of TGX-221 and its analog BL05 are shown in Scheme 1.
Synthesis of compound 1—Malonyl dichloride (3.2 mL, 32.0 mmol) was added
dropwise to a solution of 2-amino-3-bromo-5-methylpyridine (5 g, 26.7 mmol) in dry DCM
(50 mL) cooled to 0 °C. The mixture was stirred at ambient temperature (ca. 22 °C) for 48 h.
The yellow precipitate was collected by filtration, washed with DCM (3 × 50mL), and dried
under reduced pressure. The desired compound was obtained with a yield of 86 % (4.88 g),
and identity was confirmed by 1H-NMR. The crude compound was used in the next step
without any further purification. The filtrate was concentrated by rotovaporation. The
resulting residue was suspended in 100 mL of H2O, and the suspension was stirred at
ambient temperature for 1 h. The suspension was filtered and the filtrate was neutralized
with solid Na2CO3 to recover the unreacted 2-amino-3-bromo-5-methylpyridine (0.84 g).
Synthesis of compound 2—Compound 1 (4.88 g, 19.13 mmol) was suspended in dry
DCM (100 mL), and TEA (5.40 mL, 38.3 mmol) was added dropwise at 0 °C followed by
methanesulfonyl chloride (MsCl) (2.90 mL, 26.8 mmol). The mixture was stirred at ambient
temperature for 1 h. Morpholine (5.0 mL, 57.4 mmol) was added and the mixture was
refluxed for 24 h. The solvent then was removed under reduced pressure, and the mixture
was diluted with H2O to afford a pale yellow precipitate. The solid was collected by
filtration, washed with 2 × 50 mL of H2O, and dried under reduced pressure. The residue
was purified through a silica flash column using EtOAc: hexanes 3:1 as the eluting solvent.
The desired compound was obtained as a yellow solid with a yield of 42 % (2.61 g).
Synthesis of compound 3—Compound 2 (2.53 g, 7.80 mmol) in dry DMF (50 mL) was
mixed with N, N-diisopropylethylamine (4.0 mL), butyl vinyl ether (5.0 mL) and dichloro
1,1’- bis(diphenylphosphino)ferrocene palladium (II) (0.25 g, 0.20 mmol) at ambient
temperature under argon for ca. 30 min until a homogeneous solution was formed. The
solution then was heated to 120 °C and stirred for another 16 h. After the solution cooled, it
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was poured into 200 mL of 1-M HCl at 0 °C. The mixture then was stirred at ambient
temperature overnight and extracted with DCM (2 × 100 mL). The combined organic phases
were washed with water and dried over Na2SO4. Removal of the solvent under reduced
pressure followed by purification of the resulting residue through a silica flash column using
EtOAc: hexanes 3:1 as the eluting solvent led to the desired compound with a yield of 60 %
(1.35 g).
Synthesis of compound 4—Compound 3 (1.35 g, 4.69 mmol) in DCM and methanol
(5 : 1, 84 mL) was combined with NaBH4 (0.70 g, 18.5 mmol) in 5 portions at 0 °C. After
10 min, the cooling bath was removed and the mixture was stirred at ambient temperature
for 3 h. Then the mixture was cooled to 0 °C and 20 mL of H2O was added slowly. The
mixture was extracted with DCM (2 × 50 mL). The combined organic phases were washed
with water (2 × 50 mL) and brine (30 mL) and then dried over Na2SO4. Removal of the
solvent under reduced pressure followed by purification of the resulting residue through a
silica flash column using EtOAc: hexanes 3:1 as the eluting solvent led to the desired
compound with a yield of 86 % (1.17 g).
Synthesis of compound 7—A solution of compound 4 (1.17 g, 4.05 mmol) in 10 mL of
dry DCM was cooled to 0 °C, and MsCl (1.70 mL, 24.3 mmol) was added dropwise
followed by dry TEA (1.35 mL). After 10 min, the cooling bath was removed, and the
reaction proceeded at ambient temperature for ca. 4 h until TLC showed that the starting
material was consumed completely. The resulting mixture was washed with water (50 mL),
2-M aqueous NaOH (50 mL) and brine (50 mL), and then dried over Na2SO4. Removal of
the solvent under reduced pressure followed by purification of the resulting residue through
a silica flash column using EtOAc: hexanes 1:2 as the eluting solvent led to the desired
compound as a pale yellow solid with a yield of 93 % (1.39 g).
Synthesis of TGX-221(compound 5)—A solution of compound 4 (0.70 g, 1.91 mmol)
in 10 mL of dry DCM was cooled to 0 °C, and aniline (0.5 mL, 16.3 mmol) was added
dropwise followed by dry TEA (1.0 mL). The mixture was refluxed for 4 h and then stirred
at ambient temperature overnight. The mixture was washed with water (2 × 50 mL) and
brine (50 mL), and then dried over Na2SO4. Removal of the solvent under reduced pressure
followed by purification of the resulting residue through a silica flash column using EtOAc:
hexanes 3:1 as the eluting solvent led to the desired compound as a pale yellow solid with a
yield of 80 % (0.56 g).
Synthesis of 2-(Phenylamino)ethanol (compound 6)—We followed the procedure
of Bhanu et al. 30 Briefly, a mixture of aniline (4.66 g, 50 mmol) and 2-bromoethanol (4.34
g, 33 mmol) was heated at 90 °C under an argon atmosphere for 4 h. The resulting solid was
dissolved in ethyl acetate (100 mL), washed with 2-M aqueous NaOH (3x 20 mL) followed
by brine (50 mL), and then dried over Na2SO4. Removal of the solvent under reduced
pressure followed by purification of the resulting residue through a silica flash column using
EtOAc: hexanes 1:2 as the eluting solvent led to the desired compound with a yield of 89 %
(4.03 g).
Synthesis of compound 8 (BL05)—A solution of compound 5 (0.47 g, 1.28 mmol) in
10 mL of dry DCM was cooled to 0 °C, and a solution of 2-(phenylamino)ethanol (0.70 g,
5.12 mmol) in 5 mL of dry DCM was added dropwise followed by dry TEA (1 mL). After
10 min, the mixture was refluxed for ca. 15 h until TLC showed that the starting material
was consumed completely. The resulting mixture was washed with 2-M aqueous HCl, water,
saturated NaHCO3 aqueous solution and brine, and then dried over Na2SO4. Removal of the
solvent under reduced pressure followed by purification of the resulting residue through a
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silica flash column using EtOAc: hexanes 5:1 as eluting solvent led to the desired compound
with a yield of 69 % (0.36 g).
Synthesis of BL05-palmitate derivative (BL05-PA)—BL05 (compound 8) (0.10 g,
0.24 mmol) and palmatic anhydride (0.24 g, 0.48 mmol) were suspended in 10 mL of dry
DCM, and 0.20 mL of dry pyridine was added dropwise. The mixture was stirred overnight
at ambient temperature until TLC showed that the starting material was consumed
completely. The resulting mixture was washed with 2-M aqueous HCl (30 mL), water,
saturated NaHCO3 aqueous solution and brine. Removal of the solvent under reduced
pressure followed by purification of the resulting residue through a silica flash column using
EtOAc: hexanes 3:1 as the eluting solvent led to the desired compound with a yield of 95 %
(0.15 g).
Synthesis of BL05-hexanoate derivative (BL05-HA)—A solution of BL05
(compound 8) (0.18 mg, 0.45 mmol) in 5 mL of dry DCM was cooled to 0 °C, and hexanoyl
chloride (0.26 mL, 1.80 mmol) was added followed by dry pyridine (0.38 mL). After 10
min, the cooling bath was removed, and the reaction proceeded at ambient temperature
overnight until TLC showed that the starting material was consumed completely. The
resulting mixture was washed with 2-M aqueous HCl, water, saturated NaHCO3 aqueous
solution and brine. The organic phase was dried over Na2SO4. Removal of the solvent under
reduced pressure followed by purification of the resulting residue through a silica flash
column using EtOAc: hexanes 2:1 as the eluting solvent led to the desired compound as a
pale yellow solid with a yield of 91 % (0.266 g).
3. Synthesis of Azide Poly(ethylene glycol)-block-Poly(ε-caprolactone) Copolymers (N3-
PEG-PCL)
All glassware were flamed dried under vacuum and were handled under a dry argon stream.
The N3-PEG-PCL copolymer was prepared by acid catalyzed ring-opening polymerization
reaction of ε-caprolactone in the presence of N3-PEG-OH as an initiator. The typical process
is described as follows. N3-PEG-OH was azeotropically dried using anhydrous toluene
under reduced pressure. ε-caprolactone was dried over CaH2 overnight and then distilled
under vacuum. N3-PEG-OH (0.375 g, 0.0647 mmol) was dissolved in 8 mL of dry DCM,
followed by the addition of 0.75 mL of ε-caprolactone (100 eq). The polymerization was
initiated by the addition of 1-M HCl in diethyl ether (0.8 mL, 3 eq) at 25 °C. After 24 h, the
mixture was poured into diethyl ether to precipitate the copolymer. Then, the N3-PEG-PCL
copolymer was further purified by precipitation in cold acetone. The residual solvent was
removed under reduced pressure.
4. Characterization of the polymeric material
The N3-PEG-PCL was dissolved in CDCl3 for 1H-NMR spectroscopy. Gel permeation
chromatography (GPC) was used to determine the polymer molecular weight distribution.
GPC analysis was performed on a Shodex GPC LF-804 column thermostated at 40°C with
DMF and 10-mM LiCl as the mobile phase at a flow rate of 0.8 mL/min. Peaks were
detected using a refractive index detector (RID-10A, Shimadzu). Narrow molecular weight
distribution polyethylene glycols (Scientific Polymer Products Inc., Ontario, NY) were used
as standards for GPC analysis.
5. Micelle preparation
The N3-PEG-PCL (15 mg, 1.3 mmol) was dissolved in 0.5 mL of dimethylacetamide
(DMAc) and the organic solution was added dropwise to 2 mL of ddH2O with mechanical
stirring. The organic solvent was removed by overnight dialysis against phosphate buffered
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saline (PBS) using 10-kDa molecular weight cutoff (MWCO) dialysis tubing (Spectrum
Laboratories, Rancho Dominguez, CA). Drug-loaded micelles were prepared by mixing the
drugs with the copolymer in DMAc before adding ddH2O.
The aptamer, PSAMa10, was functionalized by addition of an alkyne group using the
following procedure. PSMAa10 (0.2 μmol, 3.7 mg) was dissolved in 500 μl of 0.1-M
carbonate buffer (pH 9.0). The alkyne-NHS ester (2.3 mg) was dissolved in 60 μl of DMSO,
and 6 μl of the alkyne-modified NHS ester solution was added to the carbonate buffer
containing the aptamer. After mixing for 4 h at ambient temperature, the alkyne modified
PSMAa10 was purified using a centrifugal filtration device (Amicon® Ultra Centrifugal
Filter 10K, Millipore Corp.).
The near infrared dye, IR-820, was modified to include an alkyne by conjugation of 1-
amino-3-butyne. Briefly, 150 mg of IR-820 (0.177 mmol) was dissolved in 10 mL of DMF.
Then, 61 mg of 1-amino-3-butyne (5 eq) and 123 μl of TEA (5 eq) were added. The solution
was stirred at 40 °C for 8 h. The final product was purified by silica flash chromatography
using EtOAc: methanol 1:2 as the elution solvent.
Both alkyne modified PSMAa10 and IR-820 were conjugated to the micelle’s surface by
azide alkyne Huisgen cycloaddition (i.e. click reaction). Briefly, 50 μg of alkyne modified
PSMAa10 and 100 μg of alkyne modified IR-820 were added to N3-PEG-PCL micelles (2.5
mg/mL) prepared in ddH2O. Copper sulfate (0.6 μmol/mL) and sodium ascorbate (3.0
μmol/mL) were used as a catalyst. The reaction mixture was gently stirred at ambient
temperature overnight. The modified micelles were purified by dialysis against PBS using
10,000 MWCO dialysis tubing (SnakeSkin® Pleated Dialysis Tubing, Thermo Scientific) for
24 h. To determine the extent of the reaction, the supernatant was separated from the micelle
solution using a Microcon YM-100 centrifugal concentrator (0.5-mL capacity, NMWL 100,
000, Millipore Corp.) at 11,000×g for 15 min. The filtrate was analyzed by high-
performance liquid chromatography (HPLC) (LC-2010CHT, Shimadzu).
6. Micelle characterization
The critical micelle concentration (CMC) of N3-PEG-PCL micelles was determined by
measuring the excitation ratio of pyrene using a fluorophotometer (RF-5301 PC, Shimadzu).
For example, solutions of N3-PEG-PCL micelles were prepared by serial dilution and then
incubated with 0.6-μM pyrene for 1 h at 65 °C and then 18 h at ambient temperature in the
dark. The fluorescent emission of pyrene was measured at 390 nm. The fluorescent
excitement ratio of pyrene at 339 and 334 nm changes in response to the probe’s
microenvironment polarity. A sharp increase in the 339/334 excitation ratio indicates the
CMC as the pyrene preferentially partitions into the hydrophobic core of N3-PEG-PCL
micelles.
The formation of micelles was determined by GPC (Shodex OHpak SB-803 HQ, Showa
Denko America, Inc.) using a Shimadzu 2010CHT system. GPC was performed using
ddH2O as the mobile phase with a flow rate of 0.8 mL/min, and the GPC column was
thermostated at 40 °C. Elution peaks were detected using an evaporative light scattering
detector (ELSD-LTII, Shimadzu). The size and polydispersity of micelles were measured
with a ZetaPALS (Brookhaven Instruments Corp.) using the Gaussian distribution.
The drug loading efficiency (DL %) and encapsulation efficiency (EE %) of BL05-HA in
PEG-PCL micelles were calculated according to the following equations:
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GPC micelle fraction was collected and dried by speed-vap. The dried micelle fraction was
weighed to determined weight of the polymer and drug. Then, the dried micelle was
redissolved in MeOH and drug weight in micelle was evaluated by HPLC analysis.
7. Cytotoxicity assay
The prostate cancer cell lines DU145 and LNCaP were maintained in RPMI-1640 medium,
and PC3 cells were maintained in F-12K medium (ATCC, Manassas, VA). LNCaP is a
PSMA positive cell line, whereas DU145 and PC3 are PSMA negative. Both were
supplemented with 10 % fetal bovine serum (Hyclone Laboratory Inc., Logan, Utah). Cells
were plated in 96-well flat-bottomed plates at a concentration of 5,000 cells per well in 90
μl of growth medium. After 12 h, TGX-221, BL05, or BL05-HA loaded micelles in PBS
were added at concentrations of 0, 0.1, 1, 5, 10, 50 or 100 μM. PBS and 10 μl of
trichloroacetic acid (TCA) were added to negative and positive control wells, respectively.
After 72 h, 10 μl of 55-μM resazurin blue was added to each well and incubated at 37 °C for
4 h. After incubation, the resorufin product was measured with a fluorophotometer
(SpectraMax Gemini; Molecular Devices, CA) using an excitation wavelength of 560 nm
and an emission wavelength of 590 nm. The IC50 was determined as the midpoint between
positive and negative control groups for each plate using GraphPad Prism 5 software
(GraphPad Software Inc., San Diego, CA).
8. Western blot assay
After serum starvation for 16 h, LNCaP cells were treated with 2-μM TGX-221 or BL05
and 100-ng/mL EGF for 30 min. Then, cells were pelleted and lysed with cell lysis buffer
containing protease inhibitors. Protein concentrations were determined by BCA assays, and
equal amounts of protein extract were separated on a 10 % SDS-polyacrylamide gel,
transferred to a nitrocellulose membrane and immunoblotted with anti-pAkt (Ser-473) and
Akt (Cell Signaling Technology, Inc., Danvers, MA) followed HRP-conjugated secondary
antibodies (Santa Cruz Biotech, Inc., Santa Cruz, CA). The specific bands were detected
using a chemiluminescence luminal reagent (Santa Cruz Biotech, Inc., Santa Cruz, CA).
9. In vitro drug release study
The in vitro release of the drug from N3-PEG-PCL micelles into PBS (pH 7.4) was
monitored by a dialysis method. 31 Dialysis was carried out at 37 °C under sink condition
using 10-kDa MWCO dialysis tubing (SnakeSkin®, Thermo Scientific Inc., Rockford, IL).
The initial volume of drug-loaded micelles in the dialysis tubing was 5 mL and the sink
solution was 4 L. The PBS was changed several times per day to maintain sink conditions.
After pre-determined time intervals, samples were withdrawn from the dialysis tubing and
analyzed by HPLC with a reversed phase column (TSK-GEL ® ODS-100Z, Tosoh
Bioscience) at 50 °C with UV detection at 280 nm. The chromatography conditions were a
mobile phase A of 100 % ddH2O and B of 100 % methanol at a flow rate of 1 mL/min. The
gradient program was i) a linear gradient from 50 % to 90 % solvent B over 5 min; ii) 3.5
min with 90 % solvent B; iii) 6.5 min with 100% solvent B; and iv) 10 min with 50%
solvent B. Retention times: TGX-221 6.86 min; BL05 6.93 min; BL05-HA 10.14 min and
BL05-PA 17.04 min.
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10. Uptake of PSMA-targeted micelles by prostate cancer cells
Fluorescence microscopy was used to examine cellular uptake of IR-820-labeled PSMA-
targeted micelles. PSMA negative PC3 cells and PSMA positive LNCaP cells were seeded
at a density of 1 × 106 cells in an 8.6-cm2 chamber slide system (Thermo Scientific). After
cells had attached to the microscope slide’s surface, the PC3 and LNCaP cells were
incubated with the PSMA-targeted (2.5 % weight compared with polymer concentration) or
non-targeted micelles for 6 h at 37 °C. Unbound micelles were removed by washing 3 times
with PBS. Fluorescence images were acquired using a Cy5 filter set on a Nikon Eclipse 80i
microscope equipped for epifluorescence and an Orca ER camera (Hamamatsu Inc.,
Bridgewater, NJ).
The cellular uptake and accumulation of PSMA targeted micelles (2.5 % weight compared
with polymer concentration) was quantified in LNCaP and PC3 cells. Cells were seeded in
96-well flat-bottom plates at a concentration of 5,000 cells per well in 90 μl of growth
medium. After the cells attached to the surface, 10 μl of targeted or non-targeted IR-820-
modified micelles were added at different concentrations. After 6 h of incubation, the
growth medium was removed and each well was washed with PBS. The plate fluorescence
was measured using a fluorophotometer at an excitation wavelength of 675 nm and an
emission wavelength of 750 nm.
11. Pharmacokinetic evaluation
Male Balb/c mice were maintained in a temperature-controlled room with a 12 h light/dark
cycle for at least one week prior to the study. The animal protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Kansas Medical
Center. Animals were administered BL05-HA loaded PSMA-targeted micelles or BL05-HA
prepared in propylene glycol at a dose of 30 mg/kg via tail vein injection (100 μl). Blood
samples were withdrawn after 5 min, 1, 2, 4, 6, 12 and 24 h from the saphenous vein. A 20-
μl blood sample was added to 50 μl of Alsever’s solution, which is an anticoagulant. After
gently mixing, the blood sample was centrifuged at 3,000 rpm for 10 min. Plasma was
prepared by solid phase extraction (SPE) prior to the HPLC analysis. Briefly, plasma sample
diluted with 2% NH4OH (1:3) was applied to the SPE column (Bond Elut-C18, Agilent
Technologies, Lake Forest, CA) that was pretreated with 100% MeOH and equilibrated with
100 % ddH2O. Sample was washed with 5% MeOH in ddH2O and eluted twice with 150 μl
100 % MeOH.
12. Statistical analysis
GraphPad Prism 5 software was used for statistical analysis. A t-test was used to test for
differences between two data sets, while a one-way ANOVA and Tukey post test was used
to analyze the differences when more than two data sets were compared. In all comparisons,
statistical significance was set at p ≤ 0.05.
Results
1. Drug synthesis
We successfully synthesized TGX-221, BL05 and the fatty acid prodrugs. The synthesis of
TGX-221 was accomplished with 2-amino-3-bromo-5-methylpyridine and malonyl
dichloride as the starting materials through 6 steps with an overall yield of 14 % and BL05
with an overall yield of 12 %. The structure of each compound was determined by 1H-
NMR, 13C-NMR or together with high resolution APCI-MS or ESI-MS.
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Compound 1—1H-NMR (DMSO-d6, 400 MHz): δ = 8.74 (s, 1H), 8.29 (s, 1H), 5.55 (s,
1H), 2.34 (s, 3H), which was consistent with the reported data.
Compound 2—1H-NMR (CDCl3, 400 MHz): δ = 8.72 (s, 1H), 7.87 (d, J = 1.9 Hz, 1H),
5.61 (s, 1H), 3.84-3.80 (m, 4H), 3.74-3.69 (m, 4H), 2.35 (s, 3H), which was consistent with
the reported data.
Compound 3—1H-NMR (CDCl3, 400 MHz): δ = 8.88 (s, 1H), 7.86 (d, J = 2.2 Hz, 1H),
5.66 (s, 1H), 3.84-3.79 (m, 4H), 3.67-3.62 (m, 4H), 2.79 (s, 3H), 2.38 (d, J = 1.0 Hz, 3H),
which was consistent with the reported data.
Compound 4—1H-NMR (CDCl3, 400 MHz): δ = 8.67 (s, 1H), 7.50 (d, J = 1.9 Hz, 1H),
5.63 (s, 1H), 5.25-5.18 (m, 1H), 4.63 (d, J = 5.0 Hz, 1H), 3.82 (t, J = 2.9 Hz, 4H), 3.61 (t, J =
4.2 Hz, 4H), 2.35 (d, J = 1.0 Hz, 3H), 1.63 (d, J = 6.6 Hz, 3H); 13C-NMR (CDCl3, 100
MHz): δ = 18.1, 22.1, 44.5 (x2), 49.1, 66.4 (x2), 81.1, 117.4, 122.3, 135.3, 137.3, 147.5,
159.0, 160.2; HRMS (ESI) Calc’d for C15H19N3 NaO3 (M + Na)+ : 312.1324; Found:
312.1329.
Compound 5 (TGX-221)—1H-NMR (CDCl3, 400 MHz): δ = 8.67 (s, 1H), 7.60 (d, J =
2.0 Hz, 1H), 7.13 (d, J = 7.4 Hz, 1H), 7.12 (d, J = 6.6 Hz, 1H), 6.68 (t, J = 7.3 Hz, 1H), 6.48
(d, J = 7.6 Hz, 2H), 5.68 (s, 1H), 5.15 (d, J = 5.6 Hz, 1H), 4.39 (bs, 1H), 3.81 (t, J = 5.0 Hz,
4H), 3.72-3.62 (m, 4H), 2.26 (d, J = 1.0 Hz, 3H), 1.59 (d, J = 6.8 Hz, 3H); 13C-NMR
(CDCl3, 100 MHz): δ = 18.3, 22.1, 44.6 (x2), 49.1, 66.6 (x2), 81.3, 113.2 (x2), 117.6, 122.5,
123.8, 129.2 (x2), 135.4, 137.3, 146.8, 147.5, 159.1, 160.2; HRMS (ESI) Calc’d for
C21H25N4O2 (M + H)+ : 365.1978; Found: 365.1975.
Compound 6—1H-NMR (CDCl3, 400 MHz): δ = 7.22 (dd, J = 7.4, 7.3 Hz, 2H), 6.78 (d, J
= 7.3 Hz, 1H), 6.69 (d, J = 7.7 Hz, 2H), 3.84 (t, J = 5.1 Hz, 2H), 3.32 (t, J = 4.9 Hz, 2H),
3.03 (bs, 2H).
Compound 7—1H-NMR (CDCl3, 400 MHz): δ = 8.89 (dd, J = 2.1, 1.1 Hz, 1H), 7.87 (d, J
= 2.2 Hz, 1H), 5.88 (q, J = 6.8 Hz, 1H), 5.68 (s, 1H), 3.82 (t, J = 5.2 Hz, 4H), 3.65 (t, J = 5.1
Hz, 4H), 3.16 (s, 3H), 2.39 (d, J = 0.9 Hz, 3H), 1.88 (d, J = 6.8 Hz, 3H); HRMS (ESI)
Calc’d for C16H22N3O5 S (M + H)+ : 368.1280; Found: 368.1276.
Compound 8 (BL05)—1H-NMR (CDCl3, 400 MHz): δ = 8.70 (s, 1H), 7.45 (s, 1H), 7.22
(d, J = 8.6 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 8.2 Hz, 2H), 6.76 (t, J = 6.9 Hz,
1H), 5.64-5.60 (m, 1H), 5.59 (s, 1H), 3.63-3.57 (m, 4H), 3.54 (t, J = 6.0 Hz, 2H), 3.44 (t, J =
5.6 Hz, 2H), 3.41- 3.35 (m, 4H), 2.34 (s, 3H), 1.62 (d, J = 7.0 Hz, 3H); 13C-NMR (CDCl3,
100 MHz): δ = 16.9, 18.4, 44.4 (x2), 47.3, 52.3, 60.0, 66.5 (x2), 81.3, 114.2 (x2), 117.8,
121.7, 124.3, 129.2 (x2), 135.5, 136.5, 148.0, 148.2, 159.0, 160.1; HRMS (ESI) Calc’d for
C23H29N4O3 (M + H)+ : 409.2240; Found: 409.2229.
BL05-PA—1H-NMR (CDCl3, 400 MHz): δ = 8.71 (s, 1H), 7.42 (d, J = 1.8 Hz, 1H), 7.23
(d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.2 Hz, 2H), 6.74 (t, J = 7.2 Hz,
1H), 5.61 (s, 1H), 5.60-5.57 (m, 1H), 4.16-4.09 (m, 1H), 4.00-3.93 (m, 1H), 3.67-3.59 (m,
5H), 3.58-3.49 (m, 1H), 3.41 (t, J = 4.9 Hz, 4H), 2.34 (d, J = 0.9 Hz, 3H), 2.28 (t, J = 7.5 Hz,
2H), 1.66 (d, J = 7.2 Hz, 4H), 1.61 (t, J = 7.2 Hz, 2H), 1.35-1.22 (bs, 23H), 0.90 (t, J = 7.0
Hz, 3H); 13C-NMR (CDCl3, 100 MHz): δ = 14.1, 17.5, 18.4, 22.7, 24.9, 29.2, 29.3, 29.4
(x2), 29.5 (x2), 29.6 (x2), 29.7(x2), 31.9, 34.2, 44.0, 44.4 (x2), 51.8, 61.8, 66.5 (x2), 81.3,
113.1 (x2), 117.4, 121.7, 124.2, 129.3 (x2), 135.7, 136.0, 147.7, 147.9, 159.0, 160.1, 173.7;
HRMS (ESI) Calc’d for C39H59N4O4 (M+H)+ : 647.4536; Found: 647.4528.
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BL05-HA—1H-NMR (CDCl3, 400 MHz): δ = 8.71 (s, 1H), 7.42 (d, J = 1.8 Hz, 1H), 7.23
(d, J = 8.8 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.2 Hz,
2H), 6.74 (t, J = 7.2 Hz, 1H), 5.61 (s, 1H), 5.60-5.57 (m, 1H), 4.17-4.09 (m, 1H), 4.00-3.93
(m, 1H), 3.70-3.58 (m, 5H), 3.41 (t, J = 4.9 Hz, 4H), 2.34 (d, J = 0.9 Hz, 3H), 2.28 (t, J = 7.4
Hz, 2H), 1.66 (d, J = 7.0 Hz, 3H), 1.64-1.58 (m, 1H), 1.38-1.26 (m, 5H), 0.91 (t, J = 6.8 Hz,
3H); 13C-NMR (CDCl3, 100 MHz): δ = 13.9, 17.4, 18.4, 22.3, 24.6, 31.3, 34.1, 44.0, 44.4
(x2), 51.8, 61.8, 66.5 (x2), 81.3, 113.1 (x2), 117.4, 121.7, 124.2, 129.3 (x2), 135.7, 136.0,
147.7, 147.9, 159.0, 160.1, 173.7; HRMS (ESI) Calc’d for C29H39N4O4 (M + H)+ :
507.2971; Found: 507.2955.
2. PEG-PCL micelle preparation and characterization
The N3-PEG-PCL block copolymer was synthesized by a ring opening reaction. 1H-NMR
spectra showed two main peaks at 3.67 (-OCH2CH2) and 4.08 (-
OCH2CH2CH2CH2CH2CH2CO-) that correspond to PEG and PCL, respectively. The
molecular weight of N3-PEG-PCL copolymer determined by 1H-NMR was 5,800:5,800 and
the polydispersity of this polymer measured by GPC was 1.10. The CMC was determined to
be 300 nM using the pyrene incorporation assay. Based on Gibb’s free energy of
micellization, the nanomolar CMC of PEG-PCL copolymer indicated that the micelle had
high thermodynamic stability. For 10 % (w/w) BL05-HA loaded PEG-PCL micelles, DL %
was 9.5 ± 0.2 % and EE % was 74.5 ± 4.6 %.
The N3-PEG-PCL micelles were prepared using a solvent displacement method. The PCL
block served as a hydrophobic core of the micelle and physically entrapped the poorly water
soluble anticancer drug into the micelle. GPC was used to confirm the formation of PEG-
PCL micelles. PEG-PCL micelles are known to be stable when diluted below the CMC
during GPC analysis, which reflects a high kinetic stability against dissociation.32 The
micelles’ hydrodynamic diameter from DLS with Gaussian volume weighting was
approximately 50 nm (Table 1), which is suitable for intravenous administration and
extravasation in tumors.33
3. Conjugation of PSMAa10 to PEG-PCL micelles
The alkyne modified aptamer, PSMAa10, was confirmed by ESI-MS ([M+Na]+ = 18,928.0).
The alkyne modified PSMAa10, was conjugated to the azide end group of the PEG-PCL
copolymer by the Huisgen cycloaddition click reaction. The conjugation efficiency was
determined by quantifying the unconjugated ligand remaining in the supernatant. The
amount of PSMAa10 conjugated to the N3-PEG-PCL micelle surface increased with
increasing reaction time: 1 h, 0.017 ± 0.005 (yield: 14.2 %); 3 h, 0.103 ± 0.010 (yield:
20.6%); 5 h, 0.123 ± 0.015 (yield: 24.6 %) mg PSMAa10 / mg N3-PEG-PCL. Since
precipitation occurred after 5-h, the Click reaction time was controlled at 3 h. The
conjugation of PSMAa10 to the micelle’s surface was examined by agarose gel
electrophoresis (data not shown). The near infrared fluorophore IR-820 was functionalized
with an alkyne by TEA buffered condensation with 1-amino-3-butyne. The successful
conjugation was confirmed by ESI-MS. The micelle surface also was modified with IR-820
by click reaction. The IR-820 conjugated micelles had a maximum absorption wavelength of
675 nm and an emission wavelength of 745 nm.
4. Characterization of conjugated PEG-PCL micelles
Particle sizes of different micelle formulations were determined by dynamic light scattering
(Table 1). The sizes of all of the nanoparticle formulations were smaller than 100 nm, which
is suitable for intravenous application. The in vitro release half-lives of TGX-221, BL05,
BL05-HA and BL05-PA were investigated at simulated in vivo conditions using a bath at
pH 7.4 and 37 °C (Table 1). In addition, the release half-lives of TGX-221 and its analog,
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BL05, from PEG-PCL micelles were identical, which is likely due to the similar
lipophilicity of the two compounds. TGX-221 had a calculated logPo/w of 2.14±0.68 and
BL05 was 1.81±0.67 (ALogPS 2.1, http://www.vcclab.org). The more hydrophobic ester
prodrugs, BL05-HA (logPo/w 4.15±0.31) and BL05-PA (logPo/w 8.42±0.83), had much
longer release half-lives of 5 and 6.5 days in PEG-PCL micelles, respectively. The prodrugs
tended to stay in the hydrophobic PCL core of the micelle, and they were protected from
hydrolysis in the hydrophobic core due to limited penetration of water. The aptamer
conjugated micelle was larger than the non-targeted micelle, and the conjugation of IR-820
was confirmed by observing the increased Stokes shift of fluorescent dye. The Stokes shift
of IR-820 increased after conjugation to the micelle surface due to electromagnetic
retardation 34.
5. In vitro cytotoxicity studies
The IC50s of TGX-221, BL05 and BL05-HA were determined in DU145, PC3 and LNCaP
cells (Table 2). BL05-PA was not soluble in PBS with 1 % DMSO, and it was not tested
further. TGX-221, BL05 and BL05-HA showed selective cytotoxicity to LNCaP cells,
which may be due to the deficiency of PTEN in this cell line and the accumulation of PIP3
in the cells. A Western blot was performed to determine if both TGX-221 and BL05 are
involved in the same cell signaling pathway that contributes to the selective cytotoxicity. As
demonstrated by Western blot, TGX-221 and BL05 inhibited phosphorylation of Akt
(Figure 2), which in turn indicated the inhibitor of PI3K activity.
The cytotoxicity of empty micelles, PSMA-targeted empty micelles, IR-820-labeled empty
micelles and IR-820-labeled PSMA-targeted micelles was examined in DU145 prostate
cancer cells (Figure 3). The drug free targeted micelles did not inhibit cell growth. However,
the dye-labeled micelles did inhibit cell growth, so they were not characterized further in
vivo.
6. Micelle formulation effects on cellular uptake of the drug
The DU145 cells were treated with BL05-HA in DMSO and BL05-HA loaded in non-
targeted micelles. The solubility of BL05-HA in 5 % DMSO was determined to be 32.35
μg/ml (49.86 μM). After a 12-h treatment, the cell culture medium was analyzed for
extracellular drug content by HPLC, and the drug uptaken by the cells was quantified
(Figure 4). Micelle formulations significantly improved the cellular uptake at all
concentrations, also DMSO was not required to solubilize BL05-HA in the micelle
formulation.
7. PSMAa10 targeting improved cellular uptake of both micelles and drug by PSMA-
positive cells
LNCaP cells (PSMA +) were treated with PSMA-targeted and IR-820-labeled micelles with
increasing substitutions of the aptamer. The micelle uptake was estimated by the relative
fluorescence intensity of the IR-820. The fluorescence increased with increasing aptamer
substitution: 1 %, 325 ± 103.410; 2.5 %, 574.554 ± 33.614; 5 %, 704.055 ± 73.235 and 10
%, 945.311 ± 145.445 RFU.
Confocal microscopy was used to examine if PSMA targeting can improve the micelle
uptake by PSMA presenting cells. The aptamer did not improve the micelle uptake in the
PSMA-negative PC3 cells. However, in the PSMA-positive LNCaP cells, we detected more
fluorescence signal in cells treated with PSMA-targeted micelles (Figure 5). The uptake was
then quantified with a fluorescence plate reader. The fluorescence signal was significantly
higher in PSMA-positive cells (LNCaP) treated with PSMA-targeted micelles. However, in
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PSMA-negative PC3 cells, the fluorescence was not enhanced by addition of PSMA to the
micelles (Figure 6).
The effect of PSMA-targeting of micelles on the cellular uptake of BL05-HA was examined
in both DU145 (PSMA -) and LNCaP (PSMA +) cells (Figure 7). PSMA-targeted micelles
significantly improved the drug uptake in PSMA-positive LNCaP cells but not PSMA-
negative DU145. In addition, BL05-HA formulated in PSMA-targeted micelles significantly
reduced LNCaP cell viability compared to the naked drug, whereas BL05-HA in non-
targeted micelles was no more effective than the naked drug. In PSMA negative cells, this
significant effect was not observed (Figure 8) (p > 0.05).
8. Pharmacokinetic evaluation
The pharmacokinetics of naked BL05-HA and BL05-HA formulated in PSMA-targeted
micelles were compared in male Balb/c mice (n = 3). The initial drug plasma concentration
(C0) of the micelle formulation was 1.42-fold greater than the naked drug (Figure 9). The
plasma concentration of BL05 delivered by PSMA-targeted micelles was higher than the
naked drug at all time points. A two-compartment pharmacokinetic model was selected to
describe the biexponential nature of the pharmacokinetics disposition of PEG-PCL micelle
formulation, whereas one-compartment model was used in BL05-HA naked drug and the
related pharmacokinetic parameters are listed in Table 3. The area under the plasma
concentration time curve (AUC0-24h) of the micelle formulation was 2.27-fold greater than
that of the naked drug and the concomitant total body clearance was 17.5-fold lower.
Discussion
Prostate cancer is by far the most commonly diagnosed cancer among Western Males. Most
anticancer drugs are administered intravenously or orally to achieve systemic distribution,
and the non-specific uptake of anticancer drugs may cause damage to healthy rapidly
dividing cells, such as bone marrow and hair.35, 36 Nanoparticles can passively or actively
target to tumor tissue and minimize the side effects of conventional chemotherapies, such as
sexual dysfunction, cardiac toxicity, gastrointestinal damage, and neurotoxicity.37 The leaky
endothelial vasculature of tumor tissues and the size properties of nanoparticles play a
significant role in passive targeting,38 due to the EPR effect. Improved targeting can be
achieved by decorating the nanoparticle surface with a tumor specific targeting molecule,
such as a monoclonal antibody or nucleic acid.39 The tumor specific targeting molecules can
bind to tumor cells and increase the intracellular concentration of the drug by receptor-
mediated endocytosis. In this study, we formulated a prostate cancer cell-targeted
nanocarrier that can enhance the efficacy of an encapsulated anticancer drug against prostate
cancer cells and also optimize the pharmacokinetic disposition of the drug in a mouse model
because of the encapsulated carrier. We targeted the carriers to prostate cells with the PSMA
aptamer, because this small ligand has nM affinities for the PSMA receptor, which is
ubiquitous to clinical prostate cancers.40 We conjugated the ligand to pre-formed micelles.
This approach is expected to result in a more homogenous distribution of the ligands among
the nanoparticles than other approaches, such as attaching ligands to the monomers before
formation or drug encapsulation. The resulting triazole linker also is more resistant to
hydrolytic and enzymatic cleavage than esters or amides formed by carbodiimide
chemistries.
TGX-221 showed selective cytotoxicity against LNCaP cells, which was consistent with a
previous report.13 TGX-221 and its analog, BL05, showed similar toxicity in different
prostate cancer cell lines, and Western blotting confirmed their inhibitory effects on
phosphorylation of Akt in LNCaP cells. The modification of the aniline nitrogen did not
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affect the drug activity significantly, which is possible if only the morpholinechromone ring
system and aniline structure contribute to the binding to PI3K beta subunit.41
Drug interaction and association with the hydrophobic core of the micelle can influence a
drug’s release rate.42 Both TGX-221 and BL05 did not stay in the hydrophobic core of PEG-
PCL micelles, which may be due to the amphiphilic nature of these molecules; therefore, the
hydrophobic character of the drug was modified. The addition of hydrophobic fatty esters
increased the encapsulation efficiency, so we postulated that the long carbon chain may
decrease the release rate by making the drug more favorable to the hydrophobic core.43, 44
The fatty acid prodrugs are susceptible to intra- and extra-cellular esterases and hydrolysis,
so the parent drug is expected to reform rapidly after the drug is released from micelles.
The in vitro cytotoxicity study showed that both PSMA-targeted and non-targeted empty
micelles were not toxic to DU145 cells. This was not unexpected, since both PEG and PCL
polymers are already FDA approved for use in humans and PSMAa10 is made of a single
stranded oligonucleotide. However, inhibitory effects were observed with IR-820 labeled
PEG-PCL micelles. The toxic effect came from the dye, IR-820, which was reported to
significantly inhibit cell growth at concentrations greater than 5 μM.34 Therefore, the
IR-820 labeled non-targeted and targeted micelles were only used for examining delivery
efficiency, and not for further in vivo characterization.
Due to the change of partition and diffusion coefficients, BL05-HA may have lower
membrane permeability compared to its parent drug, BL05, and TGX-221. Thus, the passive
diffusion rate of the naked drug to the cells could be lower. The micelle formulation
significantly improved cellular uptake of BL05-HA. This is because internalization of PEG-
PCL micelles can enhance cellular uptake of encapsulated drugs.45
We found that encapsulating BL05-HA with PSMA targeted PEG-PCL micelles increased
cytotoxicity in LNCaP cells but not in PC3 cells. This can be explained by the enhanced
cellular uptake of the carrier by PSMA-positive cells through a receptor-mediated pathway.
Cellular uptake of the naked drug is driven by a concentration gradient. After equilibrium is
established, no more drug can enter into the cells. The PEGylated surface of the micelles
reduces interaction with the cell surface. Therefore, the cytotoxicities of naked drug and the
untargeted drug-loaded micelles in LNCaP and PC3 cells were not significantly different. In
PSMA positive cells, the receptor mediated transport of PSMA-targeted micelles improved
drug delivery into cells. This significantly enhanced cytotoxicity in PSMA-positive cells.
Since the expression of PSMA on PSMA-negative cells was extremely low, the effect of
PSMA-targeting was not significant (p > 0.05).
A two-compartment model was used to describe the pharmacokinetic (PK) disposition of the
PEG-PCL micelle formulation. The PK profile showed that the plasma drug concentration
declines biexponentially as the sum of distribution and elimination processes. The rapid drug
concentration decrease in initial phase was due to the drug’s distribution from the central
compartment into the peripheral compartments. Drug metabolism and excretion contributed
to the gradual decrease in the plasma concentration during the beta phase. In the
pharmacokinetics study, we have shown that the PEGylated micelles can increase the
plasma AUC and detectable systemic circulation of the drug by avoiding clearance by the
reticuloendothelial system (RES) and kidneys. The RES consists primarily of monocytes
and macrophages in the spleen and liver that are responsible for clearing molecules bound
with serum proteins. The kidneys also clear unbound drugs by glomerular filtration that are
below the renal exclusion limit of ca. 20-60 kDa. Stealth nanoparticles surface-modified
with PEG can avoid clearance by the RES and kidneys, thus they have prolonged circulation
half-lives in the plasma.46 This approach has been used to optimize pharmacokinetic
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disposition of nanoparticles and enhance drug delivery.46, 47 In this study, the high Vd value
of naked BL05-HA may be due to its high tissue distribution. A rapid total body clearance
rate is also apparent. The micelle formulation significantly reduced the Vd by minimizing
non-specific tissue distribution and the drug was consequently retained within the vascular
system. This could also reduce toxicity to normal tissues by reducing their exposure to the
drug through non-specific distribution.
Conclusions
The synthesis of TGX-221, the analog BL05, and the BL05-HA and BL05-PA prodrugs
were successfully accomplished. Both TGX-221 and its analog BL05 had an inhibitory
effect on phosphatation of Akt in PTEN-deficient LNCaP cells. Encapsulation of BL05-HA
in PEG-PCL micelles resulted in sustained release over several days. In vitro, we have
shown that micelles targeted with PSMAa10 and loaded with BL05-HA significantly inhibit
the growth of PSMA-positive prostate cancer cells but not PSMA-negative cells. In vivo
pharmacokinetics demonstrated that PSMA-targeted micelles significantly increased the
AUC and decreased the total body clearance rate of the drug. These findings suggest that
PSMA-targeted micelles are a promising drug delivery vehicle for developing PI3-kinase
inhibitor treatments of PSMA positive prostate cancers. A future study will examine the
efficacy of this formulation in xenografts of human prostate cancer.
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Structure of (a) TGX-221; (b) BL05; (c) BL05-HA and (d) BL05-PA.
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Western blot analysis of Akt phosphorylation on Ser473 and total Akt protein levels with
different treatments. Both TGX-221 and BL05 showed inhibitory effects on the
phosphorylation of Akt.
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Cytotoxicity of empty micelles in DU145 cells (Mean ± SD).
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The micelle formulation improved DU145’s uptake of BL05-HA (Mean ± SD). (*: p <
0.001)
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Fluorescence imaging study of cell uptake of fluorescent PSMA-targeted micelles in PSMA-
positive LNCaP cells. A: PC3 cells treated with non-targeted micelles; B: PC3 cells treated
with PSMA-targeted micelles; C: LNCaP cells treated with non-targeted micelles; D:
LNCaP cells treated with PSMA-targeted micelles.
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Uptake of micelles by (a) PC3 cells; and (b) DU145 cells (Mean ± SD). (*: p < 0.05; **: p <
0.01)
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PSMA-targeted micelles improved drug uptake by PSMA positive cells. Drug uptake by (a)
PSMA-negative DU145 cells and (b) PSMA-positive LNCaP cells treated with targeted or
non-targeted formulations (Mean ± SD). (*: p < 0.001)
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IC50s of different formulations of BL05-HA in LNCaP and DU145 cells (Mean ± SE). (*: p
< 0.01; ˆ: p > 0.05)
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Plasma BL05 concentration versus time disposition (Mean ± SD) (n = 3).
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Synthesis of TGX-221 (Compound 5) and BL05 (Compound 8).
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Table 1
Characterization of different PEG-PCL micelle formulations. All of the formulations had particle sizes that
were smaller than 100 nm. The in vitro release half-life was improved by encapsulating more hydrophobic
prodrugs.
Size (nm) (Mean ± SD) In vitro Release Half-life
Empty Micelle 27.6 ± 0.2 -
PSMA-targeted Micelle 40.5 ± 0.8 -
TGX-221 Loaded Micelle (5% w/w) 54.5 ± 0.3 <1h
BL05 Loaded Micelle (5% w/w) 59.8 ± 2.2 < 1 h
BL05-HA Loaded Micelle (5% w/w) 49.9 ± 0.5 5 days
BL05-PA Loaded Micelle (5% w/w) 29.9 ± 0.1 6.5 days
BL05-HA Loaded PSMA-targeted Micelle 58.8 ± 0.9 -
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Table 2
IC50 of TGX-221, BL05 and BL05-HA in different prostate cancer cell lines. All of the drugs showed
selective cytotoxicity to PSMA-positive LNCaP cells. (n=6)
TGX-221 (μM) (Mean ± SE) BL05 (μM) (Mean ± SE) BL05-HA (μM) (Mean ± SE)
DU145 35.6 ± 0.12 32.4 ± 0.67 52.5 ± 0.15
PC3 18.2 ± 0.85 23.4 ± 0.74 21.8 ± 0.66
LNCaP 3.98 ± 0.18 4.036 ± 0.11 3.19 ± 0.12
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Table 3
Pharmacokinetic parameters after i.v. administration of BL05-HA loaded PSMA-targeted micelles and naked
BL05-HA (Mean ± SD) (n = 3).
Parameters Unit PSMA-targeted Micelle Naked BL05-HA
Vd mL 0.114 ± 0.019** 0.160 ± 0.024
C0 μg·mL-1 1.809 ± 0.420* 1.270 ± 0.207
AUC0-24h μg·h·mL-1 7.682 ± 0.784*** 3.385 ± 0.290
k h-1 0.647 ± 0.081*** 2.847 ± 0.083
k12 h-1 2.174 ± 0.749 -
k21 h-1 0.698 ± 0.195 -
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